Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity.

Unterreiner A, Touil R, Anastasi D, Dubois N, Niwa S, Calzascia T, Bornancin F.

J Vis Exp. 2019 Jan 7;(143). doi: 10.3791/58439.

PMID:
30663686
2.

The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibition.

Bardet M, Unterreiner A, Malinverni C, Lafossas F, Vedrine C, Boesch D, Kolb Y, Kaiser D, Glück A, Schneider MA, Katopodis A, Renatus M, Simic O, Schlapbach A, Quancard J, Régnier CH, Bold G, Pissot-Soldermann C, Carballido JM, Kovarik J, Calzascia T, Bornancin F.

Immunol Cell Biol. 2018 Jan;96(1):81-99. doi: 10.1111/imcb.1018. Epub 2017 Dec 21.

PMID:
29359407
3.

Selective MALT1 paracaspase inhibition does not block TNF-α production downstream of TLR4 in myeloid cells.

Unterreiner A, Stoehr N, Huppertz C, Calzascia T, Farady CJ, Bornancin F.

Immunol Lett. 2017 Dec;192:48-51. doi: 10.1016/j.imlet.2017.10.009. Epub 2017 Oct 24. No abstract available.

PMID:
29079202
4.

Exposure to sequestered self-antigens in vivo is not sufficient for the induction of autoimmune diabetes.

Ono N, Murakami K, Chan O, Hall H, Elford AR, Yen P, Calzascia T, Spencer DM, Ohashi PS, Dhanji S.

PLoS One. 2017 Mar 3;12(3):e0173176. doi: 10.1371/journal.pone.0173176. eCollection 2017.

5.

Two Antagonistic MALT1 Auto-Cleavage Mechanisms Reveal a Role for TRAF6 to Unleash MALT1 Activation.

Ginster S, Bardet M, Unterreiner A, Malinverni C, Renner F, Lam S, Freuler F, Gerrits B, Voshol J, Calzascia T, Régnier CH, Renatus M, Nikolay R, Israël L, Bornancin F.

PLoS One. 2017 Jan 4;12(1):e0169026. doi: 10.1371/journal.pone.0169026. eCollection 2017.

6.

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.

Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G, Woytschak J, Regnier CH, Katopodis A, Boyman O.

Sci Transl Med. 2016 Nov 30;8(367):367ra166.

PMID:
27903862
7.

Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation.

Bornancin F, Renner F, Touil R, Sic H, Kolb Y, Touil-Allaoui I, Rush JS, Smith PA, Bigaud M, Junker-Walker U, Burkhart C, Dawson J, Niwa S, Katopodis A, Nuesslein-Hildesheim B, Weckbecker G, Zenke G, Kinzel B, Traggiai E, Brenner D, Brüstle A, St Paul M, Zamurovic N, McCoy KD, Rolink A, Régnier CH, Mak TW, Ohashi PS, Patel DD, Calzascia T.

J Immunol. 2015 Apr 15;194(8):3723-34. doi: 10.4049/jimmunol.1402254. Epub 2015 Mar 11.

8.

Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.

Arduin E, Arora S, Bamert PR, Kuiper T, Popp S, Geisse S, Grau R, Calzascia T, Zenke G, Kovarik J.

Mol Immunol. 2015 Feb;63(2):456-63. doi: 10.1016/j.molimm.2014.09.017. Epub 2014 Oct 18.

PMID:
25451975
9.

Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis.

Billich A, Baumruker T, Beerli C, Bigaud M, Bruns C, Calzascia T, Isken A, Kinzel B, Loetscher E, Metzler B, Mueller M, Nuesslein-Hildesheim B, Kleylein-Sohn B.

PLoS One. 2013;8(3):e59630. doi: 10.1371/journal.pone.0059630. Epub 2013 Mar 27.

10.

Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment.

Warncke M, Calzascia T, Coulot M, Balke N, Touil R, Kolbinger F, Heusser C.

J Immunol. 2012 May 1;188(9):4405-11. doi: 10.4049/jimmunol.1200090. Epub 2012 Mar 28.

11.

Vav1 GEF activity is required for T cell mediated allograft rejection.

Haubert D, Li J, Saveliev A, Calzascia T, Sutter E, Metzler B, Kaiser D, Tybulewicz VL, Weckbecker G.

Transpl Immunol. 2012 Jun;26(4):212-9. doi: 10.1016/j.trim.2012.03.003. Epub 2012 Mar 21.

12.

Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection.

Wang C, McPherson AJ, Jones RB, Kawamura KS, Lin GH, Lang PA, Ambagala T, Pellegrini M, Calzascia T, Aidarus N, Elford AR, Yue FY, Kremmer E, Kovacs CM, Benko E, Tremblay C, Routy JP, Bernard NF, Ostrowski MA, Ohashi PS, Watts TH.

J Exp Med. 2012 Jan 16;209(1):77-91. doi: 10.1084/jem.20110675. Epub 2011 Dec 19.

13.

IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology.

Pellegrini M, Calzascia T, Toe JG, Preston SP, Lin AE, Elford AR, Shahinian A, Lang PA, Lang KS, Morre M, Assouline B, Lahl K, Sparwasser T, Tedder TF, Paik JH, DePinho RA, Basta S, Ohashi PS, Mak TW.

Cell. 2011 Feb 18;144(4):601-13. doi: 10.1016/j.cell.2011.01.011. Epub 2011 Feb 3.

14.

Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies.

Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, Dissanayake D, Dhanji S, Nguyen LT, Gronski MA, Morre M, Assouline B, Lahl K, Sparwasser T, Ohashi PS, Mak TW.

Nat Med. 2009 May;15(5):528-36. doi: 10.1038/nm.1953. Epub 2009 Apr 26. Erratum in: Nat Med. 2009 Jul;15(7):819.

PMID:
19396174
15.

Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes.

Calzascia T, Loh JM, Di Berardino-Besson W, Masson F, Guillaume P, Burkhardt K, Herrera PL, Dietrich PY, Walker PR.

Glia. 2008 Nov 15;56(15):1625-36. doi: 10.1002/glia.20715.

PMID:
18551629
16.

Aggravation of viral hepatitis by platelet-derived serotonin.

Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, Kurrer M, Cervantes-Barragan L, Ludewig B, Calzascia T, Bolinger B, Merkler D, Odermatt B, Bader M, Graf R, Clavien PA, Hegazy AN, Löhning M, Harris NL, Ohashi PS, Hengartner H, Zinkernagel RM, Lang KS.

Nat Med. 2008 Jul;14(7):756-61. doi: 10.1038/nm1780. Epub 2008 May 30.

PMID:
18516052
17.

CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity.

Calzascia T, Pellegrini M, Lin A, Garza KM, Elford AR, Shahinian A, Ohashi PS, Mak TW.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2999-3004. doi: 10.1073/pnas.0712135105. Epub 2008 Feb 14.

18.

IRAK-4 kinase activity is required for IRAK-4-dependent innate and adaptive immune responses.

Lye E, Dhanji S, Calzascia T, Elford AR, Ohashi PS.

Eur J Immunol. 2008 Mar;38(3):870-6. doi: 10.1002/eji.200737429.

19.

TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.

Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, Mak TW, Ohashi PS.

J Clin Invest. 2007 Dec;117(12):3833-45.

20.

Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells.

Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, Walker PR.

J Immunol. 2007 Jul 15;179(2):845-53. Erratum in: J Immunol. 2008 Mar 1;180(5):3612.

21.

A critical role for the innate immune signaling molecule IRAK-4 in T cell activation.

Suzuki N, Suzuki S, Millar DG, Unno M, Hara H, Calzascia T, Yamasaki S, Yokosuka T, Chen NJ, Elford AR, Suzuki J, Takeuchi A, Mirtsos C, Bouchard D, Ohashi PS, Yeh WC, Saito T.

Science. 2006 Mar 31;311(5769):1927-32.

22.

Specific ablation of the apoptotic functions of cytochrome C reveals a differential requirement for cytochrome C and Apaf-1 in apoptosis.

Hao Z, Duncan GS, Chang CC, Elia A, Fang M, Wakeham A, Okada H, Calzascia T, Jang Y, You-Ten A, Yeh WC, Ohashi P, Wang X, Mak TW.

Cell. 2005 May 20;121(4):579-591. doi: 10.1016/j.cell.2005.03.016.

23.

Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs.

Calzascia T, Masson F, Di Berardino-Besson W, Contassot E, Wilmotte R, Aurrand-Lions M, Rüegg C, Dietrich PY, Walker PR.

Immunity. 2005 Feb;22(2):175-84.

24.

Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivo.

Zarei S, Abraham S, Arrighi JF, Haller O, Calzascia T, Walker PR, Kündig TM, Hauser C, Piguet V.

J Virol. 2004 Jul;78(14):7843-5.

25.

Efficient induction of CD8 T-associated immune protection by vaccination with mRNA transfected dendritic cells.

Zarei S, Arrighi JF, Ongaro G, Calzascia T, Haller O, Frossard C, Piguet V, Walker PR, Hauser C.

J Invest Dermatol. 2003 Oct;121(4):745-50.

26.

Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain.

Calzascia T, Di Berardino-Besson W, Wilmotte R, Masson F, de Tribolet N, Dietrich PY, Walker PR.

J Immunol. 2003 Sep 1;171(5):2187-91.

27.

T-cell immune responses in the brain and their relevance for cerebral malignancies.

Walker PR, Calzascia T, de Tribolet N, Dietrich PY.

Brain Res Brain Res Rev. 2003 May;42(2):97-122. Review.

PMID:
12738053
28.

All in the head: obstacles for immune rejection of brain tumours.

Walker PR, Calzascia T, Dietrich PY.

Immunology. 2002 Sep;107(1):28-38. Review. No abstract available.

29.

Loss of Fas (CD95/APO-1) expression by antigen-specific cytotoxic T cells is reversed by inhibiting DNA methylation.

Walker PR, Calzascia T, Schnuriger V, Chalmers D, Saas P, Dietrich PY.

Cell Immunol. 2000 Nov 25;206(1):51-8.

PMID:
11161437
30.

The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells.

Walker PR, Calzascia T, Schnuriger V, Scamuffa N, Saas P, de Tribolet N, Dietrich PY.

J Immunol. 2000 Sep 15;165(6):3128-35.

Supplemental Content

Loading ...
Support Center